The CLEC3B (C-Type Lectin Domain Family 3 Member B) gene encodes tetranectin, a secreted glycoprotein belonging to the C-type lectin superfamily. Tetranectin is involved in regulating proteolytic processes, particularly through its interaction with plasminogen and the kringle domains of plasminogen activators, which play roles in extracellular matrix remodeling, tissue repair, and fibrinolysis. It is highly expressed in various tissues, including bone, cartilage, and certain cancers. CLEC3B antibodies are tools used to detect and study the expression, localization, and function of tetranectin in both physiological and pathological contexts. Research has linked CLEC3B dysregulation to diseases such as osteoporosis, cardiovascular disorders, and tumor progression, where altered tetranectin levels may influence cell adhesion, migration, and metastasis. In oncology, CLEC3B antibodies help explore its dual role as a potential tumor suppressor or promoter, depending on cancer type. These antibodies are also utilized in diagnostic assays and biomarker studies to correlate CLEC3B expression with clinical outcomes. Despite its established roles, the precise molecular mechanisms of tetranectin in disease pathways remain under investigation, driving ongoing interest in CLEC3B-targeted research.